BeiGene, Ltd. Sponsored ADR
(NASDAQ : BGNE)

( )
BGNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.65%88.151.3%$855.06m
AMGNAmgen Inc.
-2.71%186.701.2%$536.92m
BIIBBiogen Inc.
-4.48%216.711.3%$511.45m
ONCESpark Therapeutics, Inc.
-0.24%113.0011.2%$460.68m
GILDGilead Sciences, Inc.
-1.77%63.770.9%$455.57m
REGNRegeneron Pharmaceuticals, Inc.
-2.68%391.802.6%$275.42m
ILMNIllumina, Inc.
-3.26%308.793.5%$273.28m
VRTXVertex Pharmaceuticals Incorporated
-0.56%181.531.9%$235.95m
BPTHBio-Path Holdings, Inc.
18.94%21.98190.1%$220.64m
SRPTSarepta Therapeutics, Inc.
-3.47%122.2615.4%$207.36m
EXASExact Sciences Corporation
-3.28%89.0025.3%$185.14m
ALXNAlexion Pharmaceuticals, Inc.
-2.98%130.212.0%$179.59m
AAgilent Technologies, Inc.
-3.68%78.981.6%$135.89m
IONSIonis Pharmaceuticals, Inc.
-1.99%78.908.3%$104.26m
INCYIncyte Corporation
-2.00%85.342.5%$93.76m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.